## Guest Editorial

## A Dermatologist's Dilemma: Treatment Failure or Failure to Treat?

Shawn G. Kwatra, MD; Steven R. Feldman, MD, PhD

Too often chronic skin disease, particularly extensive disease, does not improve with topical therapy alone, which typically is thought to be due to the ineffectiveness of the medication, the resistance of immune cells, or the failure to treat the entire field of involvement. These explanations lead physicians to think that patients may need more potent and risky treatments, systemic therapies, or other approaches that address the entire field of disease.<sup>1</sup> However, in many cases treatment failure is not caused by resistant disease but by failure to treat.

When evaluating causes of treatment failure, adherence concerns often are ignored, even though poor adherence is exceedingly common. If a treatment is not working as expected, it is too easy to assume the patient's condition is resistant to the treatment. Patients can easily convince physicians that they are following medical treatment as directed.<sup>2</sup> It is possible patients are properly using medications, but clinical trials measuring treatment use have found that patients may report using the treatment in written treatment diaries even when they do not actually use the medicine.<sup>3</sup> Moreover, actual patients appear to be far less adherent than clinical trial participants. Although there may be several reasons for treatment failure, observed ineffectiveness often is due to poor adherence.

In fact, Storm et al<sup>4</sup> reported that 1 in 3 prescriptions are never even filled. Prescription fill rates were especially low for chronic diseases such as psoriasis and atopic dermatitis.<sup>4</sup> Only approximately half of prescriptions that are filled are used the prescribed

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. The authors report no conflict of interest.

Correspondence: Shawn G. Kwatra, MD, Department of

number of times, and many patients use their medications poorly and with unpredictable patterns.<sup>3,5</sup> Adherence to topical therapy is not only related to the number of times the medication is applied but also to the quality of application. Among first-time dermatology patients in one study, 94% (16/17) used a suboptimal dose of topical therapy.<sup>6</sup> These issues with adherence are linked to poor outcomes in patients with varied dermatologic conditions such as acne, atopic dermatitis, and psoriasis.<sup>7</sup> Patients with more severe disease are less likely to be adherent to treatment than patients with milder disease.8 Indeed, it is expecting a lot for patients with 5% to 10% or more body surface area involvement to use topical treatments on all of their lesions on a regular basis! For many of these patients, topical therapies may not be rational treatment options if they do not feel they can treat all lesions on a regular basis. Systemic treatments may be first-line approaches for these patients because adherence to topical treatments may be entirely impractical.

Although there clearly is a time to consider the possibility of treatment failure, physicians should first consider, assess, and address failure-to-treat concerns before treatment resistance is assumed. Treatment outcomes can be improved by encouraging patients to use their medications more adequately. There are 3 pillars of successful dermatologic care: making the right diagnosis, choosing the right treatment, and encouraging patients to take their medication. The foundation of adherence is a trusting physician-patient relationship, one that overrides the patient's fear of drug treatment. Other approaches such as scheduling an early office visit to minimize the apparent burden of treatment and tailoring treatments to patient preferences (ie, choosing vehicles that patients do not mind using) can result in improved use of medication and better treatment outcomes.9-11 Providing the patient with written information on why the treatment is helpful and how it should be used also may be beneficial.<sup>12</sup> Putting side effects in perspective, which often is no easy task, also needs to be a consideration. Oftentimes patients may be able to clear their condition with a medication they have already tried but did not use

VOLUME 90, NOVEMBER 2012 219

Copyright Cutis 2012. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Both from the Department of Dermatology, Center for Dermatology Research, Wake Forest University School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences, Wake Forest University School of Medicine.

Dermatology, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (Kwatra.shawn@gmail.com).

well without the need to try more toxic or costly systemic therapies. Addressing these concerns that affect patient adherence may help to achieve more favorable treatment outcomes.

## REFERENCES

- 1. Silverberg NB. The field effect. Cutis. 2011;87:215-216.
- Nolan BV, Feldman SR. Adherence, the fourth dimension in the geometry of dermatological treatment. Arch Dermatol. 2009;145:1319-1321.
- Carroll CL, Feldman SR, Camacho FT, et al. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51:212-216.
- Storm A, Andersen SE, Benfeldt E, et al. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic [published online ahead of print May 7, 2008]. J Am Acad Dermatol. 2008;59:27-33.
- Ali SM, Brodell RT, Balkrishnan R, et al. Poor adherence to treatments: a fundamental principle of dermatology. *Arch Dermatol.* 2007;143:912-915.
- Storm A, Benfeldt E, Andersen SE, et al. A prospective study of patient adherence to topical treatments: 95% of patients underdose [published online ahead

of print September 24, 2008]. J Am Acad Dermatol. 2008;59:975-980.

- 7. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. *Am J Clin Dermatol.* 2006;7:231-236.
- Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408-414.
- Yentzer BA, Gosnell AL, Clark AR, et al. A randomized controlled pilot study of strategies to increase adherence in teenagers with acne vulgaris. J Am Acad Dermatol. 2011;64:793-795.
- Sagransky MJ, Yentzer BA, Williams LL, et al. A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis. *Arch Dermatol.* 2010;146:1428-1430.
- 11. Feldman SR. Practical Ways to Improve Patients' Treatment Outcomes. Winston-Salem, NC: Medical Quality Enhancement Corporation; 2009.
- Robinson JK, Turrisi R, Mallett KA, et al. Efficacy of an educational intervention with kidney transplant recipients to promote skin self-examination for squamous cell carcinoma detection [published online ahead of print February 21, 2011]. Arch Dermatol. 2011;147: 689-695.

